Press Release
September 18, 2017

Skanska Signs PTC and Alexion Pharmaceuticals to its 121 Seaport Office Development in Boston’s Seaport District

Goodwin’s Real Estate Leasing team advised Skanska in its lease agreements with PTC Inc. and Alexion Pharmaceuticals as both companies relocate their headquarters to Boston’s Seaport District at 121 Seaport Blvd., Skanska’s renowned 17-story, 400,000 square-feet state-of-the-art elliptical office tower.

Now fully leased, 121 Seaport is a Class-A office building targeting LEED® Platinum certification in the first quarter of 2018. The office tower sits in the heart of Boston’s Seaport District, across from District Hall and Seaport Square Green, on Boston’s most sustainable block, which is also home to Skanska’s 101 Seaport and Watermark Seaport developments. Designed by CBT Architects, the building’s distinctive design will enhance the area’s architectural landscape, maximize the skyline visible from Seaport Square Green and reduce solar heat gain when completed.

PTC, a global provider of technology, is the building’s first tenant, and will take over 250,000 square feet in early 2019, occupying two-thirds of the tower, making it the largest lease to be signed in Boston this year.

Alexion, a global biopharmaceutical company, will occupy 150,000 square feet in the building starting June 2018.

Skanska USA is one of the largest, most financially sound development and construction companies in the U.S., serving a broad range of clients including those in transportation, power, industrial, water/wastewater, healthcare, education, sports, data centers, government, aviation and commercial.

The Goodwin team was led by partner Alex Randall.

For additional details on both leases, please read the PTC press release and the Alexion Pharmaceuticals press release.